PDF(Pubmed)
Abstract：
UNASSIGNED: Erythema nodosum (EN) is a self-limited septal panniculitis that presents with fever, arthralgia, and arthritis. Tumor necrosis factor alpha (TNF-α) inhibitor such as golimumab has been found to treat EN in inflammatory bowel diseases (IBD). We herein report the paradoxical occurrence of EN following golimumab for ankylosing spondylitis.
UNASSIGNED: A 34-year-old female presented in June 2022 with a complaint of \'sores\' on her feet that intermittently presented for approximately 5 months but that had worsened dramatically in the last 24 h. The patient had an 8-year history of ankylosing spondylitis for 7 years. Subcutaneous golimumab was administered every 4 weeks as she had not responded to other treatments. Twenty-four hours after the fifth subcutaneous injection, painful, erythematous nodules appeared, histologically compatible with EN. Despite this side effect, we continue therapy due to the good response and efficacy.
UNASSIGNED: Skin reactions were associated with the treatment with golimumab, including warm tender skin around the injection site, eruptions, itchiness, and sometimes a full-body rash. Golimumab was successfully used in treating EN in Crohn\'s disease. Because our patient continued on golimumab, the temporal association of EN flares with therapeutic injection and the lack of any etiology support a direct causal relationship between EN and golimumab treatment.
UNASSIGNED: TNF-α inhibitors are useful in treating Crohn\'s disease patients with EN, although it may present as an adverse effect of this treatment. Further work is needed.
UNASSIGNED: A 34-year-old female presented in June 2022 with a complaint of \'sores\' on her feet that intermittently presented for approximately 5 months but that had worsened dramatically in the last 24 h. The patient had an 8-year history of ankylosing spondylitis for 7 years. Subcutaneous golimumab was administered every 4 weeks as she had not responded to other treatments. Twenty-four hours after the fifth subcutaneous injection, painful, erythematous nodules appeared, histologically compatible with EN. Despite this side effect, we continue therapy due to the good response and efficacy.
UNASSIGNED: Skin reactions were associated with the treatment with golimumab, including warm tender skin around the injection site, eruptions, itchiness, and sometimes a full-body rash. Golimumab was successfully used in treating EN in Crohn\'s disease. Because our patient continued on golimumab, the temporal association of EN flares with therapeutic injection and the lack of any etiology support a direct causal relationship between EN and golimumab treatment.
UNASSIGNED: TNF-α inhibitors are useful in treating Crohn\'s disease patients with EN, although it may present as an adverse effect of this treatment. Further work is needed.
摘要：
■结节性红斑（EN）是一种表现为发热的自限性间隔脂膜炎，关节痛,和关节炎。已发现肿瘤坏死因子α(TNF-α)抑制剂如戈利木单抗治疗炎症性肠病(IBD)中的EN。我们在此报告戈利木单抗治疗强直性脊柱炎后EN的反常发生。
■一名34岁女性于2022年6月就诊，她的脚上出现了“疮”，间歇性出现了大约5个月，但在最后24小时内急剧恶化。该患者有8年的强直性脊柱炎病史，持续7年。每4周给予皮下戈利木单抗,因为她对其他治疗没有反应。第五次皮下注射24小时后，痛苦,出现红斑结节,组织学上与EN兼容。尽管有这种副作用,我们继续治疗，由于良好的反应和疗效。
■皮肤反应与戈利木单抗治疗有关，包括注射部位周围温暖柔软的皮肤，喷发,瘙痒，有时全身出现皮疹.Golimumab已成功用于治疗克罗恩病的EN。因为我们的病人继续服用戈利木单抗，EN耀斑与治疗性注射的时间相关性以及缺乏任何病因支持EN和戈利木单抗治疗之间的直接因果关系.
■TNF-α抑制剂可用于治疗克罗恩病患者的EN，尽管它可能是这种治疗的不良反应。需要进一步的工作。
■一名34岁女性于2022年6月就诊，她的脚上出现了“疮”，间歇性出现了大约5个月，但在最后24小时内急剧恶化。该患者有8年的强直性脊柱炎病史，持续7年。每4周给予皮下戈利木单抗,因为她对其他治疗没有反应。第五次皮下注射24小时后，痛苦,出现红斑结节,组织学上与EN兼容。尽管有这种副作用,我们继续治疗，由于良好的反应和疗效。
■皮肤反应与戈利木单抗治疗有关，包括注射部位周围温暖柔软的皮肤，喷发,瘙痒，有时全身出现皮疹.Golimumab已成功用于治疗克罗恩病的EN。因为我们的病人继续服用戈利木单抗，EN耀斑与治疗性注射的时间相关性以及缺乏任何病因支持EN和戈利木单抗治疗之间的直接因果关系.
■TNF-α抑制剂可用于治疗克罗恩病患者的EN，尽管它可能是这种治疗的不良反应。需要进一步的工作。
